MX2009009320A - Uso de antagonistas de lhrh para el tratamiento de sintomas del tracto urinario inferior, en particular vejiga hiperactiva y/o hiperactividad detrusora. - Google Patents

Uso de antagonistas de lhrh para el tratamiento de sintomas del tracto urinario inferior, en particular vejiga hiperactiva y/o hiperactividad detrusora.

Info

Publication number
MX2009009320A
MX2009009320A MX2009009320A MX2009009320A MX2009009320A MX 2009009320 A MX2009009320 A MX 2009009320A MX 2009009320 A MX2009009320 A MX 2009009320A MX 2009009320 A MX2009009320 A MX 2009009320A MX 2009009320 A MX2009009320 A MX 2009009320A
Authority
MX
Mexico
Prior art keywords
overactive bladder
urinary tract
detrusor overactivity
lower urinary
treatment
Prior art date
Application number
MX2009009320A
Other languages
English (en)
Spanish (es)
Inventor
Juergen Engel
Oliver Bauer
Original Assignee
Aeterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh
Publication of MX2009009320A publication Critical patent/MX2009009320A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2009009320A 2007-03-05 2008-03-05 Uso de antagonistas de lhrh para el tratamiento de sintomas del tracto urinario inferior, en particular vejiga hiperactiva y/o hiperactividad detrusora. MX2009009320A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89289907P 2007-03-05 2007-03-05
EP07103483A EP1967202A1 (fr) 2007-03-05 2007-03-05 Utilisation d'antagonistes LHTH pour le traitement des symptômes de tractus urinaires faibles, en particulier la vessie hyperactive et/ou hyperactivité du détrusor
PCT/EP2008/052640 WO2008107446A1 (fr) 2007-03-05 2008-03-05 Utilisation d'antagonistes de lhrh pour traitement de symptômes du tractus urinaire inférieur, vessie hyperactive et/ou hyperactivité du détrusor en particulier

Publications (1)

Publication Number Publication Date
MX2009009320A true MX2009009320A (es) 2009-09-10

Family

ID=38006763

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009320A MX2009009320A (es) 2007-03-05 2008-03-05 Uso de antagonistas de lhrh para el tratamiento de sintomas del tracto urinario inferior, en particular vejiga hiperactiva y/o hiperactividad detrusora.

Country Status (13)

Country Link
US (1) US20090075937A1 (fr)
EP (2) EP1967202A1 (fr)
JP (1) JP2010520257A (fr)
KR (1) KR20100014923A (fr)
CN (1) CN101657211A (fr)
AU (1) AU2008223841A1 (fr)
BR (1) BRPI0808488A2 (fr)
CA (1) CA2679690A1 (fr)
IL (1) IL200182A0 (fr)
MX (1) MX2009009320A (fr)
RU (1) RU2009136642A (fr)
WO (1) WO2008107446A1 (fr)
ZA (1) ZA200905306B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240697A1 (en) 2007-11-02 2010-09-23 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
EP2095818A1 (fr) * 2008-02-29 2009-09-02 AEterna Zentaris GmbH Utilisation d'antagonistes LHRH dans des doses n'impliquant pas de castration
WO2010118291A2 (fr) 2009-04-10 2010-10-14 Auspex Pharmaceuticals, Inc. Modulateurs à base d'acide biphényl-3-carboxylique du béta-3-adrénorécepteur
CN105663059A (zh) 2009-05-01 2016-06-15 辉凌公司 用于治疗前列腺癌的组合物
EP2266568A1 (fr) * 2009-05-26 2010-12-29 Æterna Zentaris GmbH Composition pharmaceutique comprenant d'antagonistes de LHRH et d'inhibiteurs de PDE V pour le traitement des états dépendants de l'hormone sexuel
EP2266567A1 (fr) * 2009-05-26 2010-12-29 Æterna Zentaris GmbH Composition pharmaceutique comprenant de Cetrorelix e d'inhibiteurs de PDE V pour le traitement des étas dépendants de l'hormone sexuel
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
MX353105B (es) * 2010-08-03 2017-12-19 Velicept Therapeutics Inc Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva.
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
EP2447276A1 (fr) 2010-10-27 2012-05-02 Ferring B.V. Procédé pour la fabrication du degarelix et de ses intermédiaires
RS55457B1 (sr) 2010-10-27 2017-04-28 Ferring Bv Postupak za proizvodnju degareliksa i njegovih intermedijara
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
RU2657444C2 (ru) 2012-06-01 2018-06-13 Ферринг Б.В. Получение дегареликса
EP2897616A1 (fr) 2012-09-18 2015-07-29 TARIS Biomedical LLC Systèmes et procédés d'administration de médicament pour le traitement d'un dysfonctionnement de la vidange de la vessie et d'autres troubles du tractus urinaire inférieur
AU2015358378A1 (en) 2014-12-03 2017-06-29 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
PT3365321T (pt) 2015-10-23 2024-01-12 B3Ar Therapeutics Inc Zwiterião de solabegron e suas utilizações
CN112839653A (zh) 2018-08-01 2021-05-25 塔里斯生物医药公司 使用曲司氯铵治疗膀胱过度活动症的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
CN1879630A (zh) * 1998-06-11 2006-12-20 内部研究股份有限公司 雄－5－烯－3β,17β－二醇的药物组合物及其用途
AU2001295359A1 (en) * 2000-10-30 2002-05-15 University Of Zurich GnRH analogues for treatment of urinary incontinence
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
NZ533430A (en) * 2001-12-14 2005-12-23 Zentaris Gmbh Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR)
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
DE102004033902A1 (de) * 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)

Also Published As

Publication number Publication date
CN101657211A (zh) 2010-02-24
JP2010520257A (ja) 2010-06-10
CA2679690A1 (fr) 2008-09-12
RU2009136642A (ru) 2011-04-10
KR20100014923A (ko) 2010-02-11
BRPI0808488A2 (pt) 2014-07-15
AU2008223841A1 (en) 2008-09-12
US20090075937A1 (en) 2009-03-19
EP2131854A1 (fr) 2009-12-16
IL200182A0 (en) 2010-04-15
WO2008107446A1 (fr) 2008-09-12
EP1967202A1 (fr) 2008-09-10
ZA200905306B (en) 2010-04-28

Similar Documents

Publication Publication Date Title
MX2009009320A (es) Uso de antagonistas de lhrh para el tratamiento de sintomas del tracto urinario inferior, en particular vejiga hiperactiva y/o hiperactividad detrusora.
MX2010009447A (es) Uso de antagonistas de lhrh a dosis no castrantes.
Bai et al. Management of catheter-related bladder discomfort in patients who underwent elective surgery
Park et al. A randomized, double-blind trial of palonosetron compared with ondansetron in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery
IL207440A (en) Use of an antagonist antibody against a related peptide-calcitonin gene (cgrp) in the preparation of a drug for the prevention and / or treatment of chronic pain and / or symptoms of chronic pain and pharmaceutical preparations and kits containing it
WO2009021058A3 (fr) Compositions pharmaceutiques pour le traitement de la douleur chronique et de la douleur associée à une neuropathie
WO2008050329A3 (fr) NOUVEAUX ARNsi ET PROCÉDÉS D'UTILISATION DE CEUX-CI
NZ702485A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
NZ587297A (en) Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat inflammatory pain
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
TW200733975A (en) Pharmaceutical combination for the treatment of luts
WO2011107653A8 (fr) Méthode de traitement de la maladie de parkinson
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions
TW200727905A (en) Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
WO2008051496A3 (fr) Utilisation d'antagonistes il-1 pour traiter la goutte ou la pseudo-goutte
RU2011147390A (ru) Новое применение
MY162440A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
JP2016505561A5 (fr)
Chen et al. The chemokine CX3CL1/fractalkine interferes with the antinociceptive effect induced by opioid agonists in the periaqueductal grey of rats
EA201791732A1 (ru) Безопасное введение десмопрессина
MX338130B (es) Compuestos de benzazepina.
RU2016152226A (ru) Фармацевтический состав для уменьшения частоты мочеиспускания и способ его применения
De Berardis et al. When clozapine fails: augmentation strategies in the management of clozapine-resistant schizophrenia
Kus et al. Effect of combined administration of aripiprazole and fluoxetine on cognitive functions in female rats exposed to ethyl alcohol
WO2007074291A3 (fr) Derives de piperidine pour pour le traitement des incontinences

Legal Events

Date Code Title Description
FA Abandonment or withdrawal